Slide 1: Half-Year Report 2026
> Zee wy i Ha I-Year vepert 2026
Slide 2: Our mission: People are at the heart of everything we do
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 2 Our mission: People are at the heart of everything we do.
Slide 3: Basilea Half-year report Letter to
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 3
Slide 4: Our purpose: making a difference to patients
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 4 Our purpose: We strive towards making a difference to patients. With expertise, foresight and persistence.
Slide 5: Basilea Half-year report Letter to
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 5
Slide 6: Highlights
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 6 Financial report Letter to shareholders 7 “Agenda 2030” 12 At a glance 16 Our business model 17 Our markets & products 18 Highlights Established strong partnerships 19 Our portfolio 20 Financial highligh
Slide 7: Letter to shareholders
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 7 Letter to shareholders previous topic next topic
Slide 8: We aim to improve patient outcomes
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 8 “We aim to improve patient outcomes by providing more effective, safer and more convenient treatment options than those currently available. ” previous topic next topic
Slide 9: Dear readers
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 9 Dear readers We are pleased to report a strong start to environment, i.e. generating sufficient financial returns, the year. Our half-year results demonstrate has historically been challenging for anti-i
Slide 10: Letter to shareholders (continued)
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 10 The commercial performance of our marketed products We are continuing to strengthen our organization and continues to reflect the strength of our business model capabilities to support future growth. T
Slide 11: Basilea Half-year report Letter to
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 11 previous topic next topic
Slide 12: Agenda 2030
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 12 “Agenda 2030” 600 ~CHF million “Agenda 2030” is Basilea’s roadmap for expected cumulative its next chapter of development and cash flow value creation. Building on our financial from Cresemba and streng
Slide 13: Commercial portfolio outlook
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 13 Commercial portfolio outlook Current phase 3 pipeline has the potential to double the 2025 in-market sales Ceftibuten-ledaborbactam Fosmanogepix Zevtera Cresemba 2025 2026 2027 2028 2029 2030 2031 2032
Slide 14: Basilea Half-year report Letter to
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 14 previous topic next topic
Slide 15: Highlights
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 15 Highlights At a glance 16 Our business model 17 Our markets & products 18 Established strong partnerships 19 Our portfolio 20 Financial highlights 22 Company highlights 2026 24 Capital Markets Day 2026
Slide 16: At a glance
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 16 At a glance We focus on developing treatments for severe bacterial & fungal infections Founded in 2000 ~ 200 employees from 28 different countries SIX Swiss Exchange stock symbol Profitable Swiss commer
Slide 17: Our business model
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 17 Our business In-license/ model External pool of acquire novel anti-infective Value-sharing financial structures with limited upfront and development potential assets assets milestone payments e.g. fosm
Slide 18: Our markets & products
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 18 Our markets & products Antifungals Antibiotics 6.5 7.7 The antifungals The antibiotics 4.5 15.6 market is estimated at USD market is estimated at USD billion million people billion million people are af
Slide 19: Established strong partnerships
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 19 Established strong partnerships Commercialization through partnerships with License Partners global, regional and local specialized pharma- ceutical partners Distribution Partners Offsetting R&D investm
Slide 20: Our portfolio
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 20 For more information on our Our portfolio portfolio, please visit page 29. Assets Preclinical Phase 1 Phase 2 Phase 3 Market Commercial Cresemba® isavuconazole Invasive aspergillosis and mucormycosis (U
Slide 21: Basilea Half-year report Letter to
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 21 previous topic next topic
Slide 22: Financial highlights
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 22 Financial highlights in CHF million, rounding consistently applied 232.4 208.5 Total revenue 157.6 119.0 +14.4% year-on-year 104.0 Other revenue 84.9 13.5 26.7 +97.8% year-on-year 76.3 90.5 Cresemba & Z
Slide 23: Operating profit, cash flow and net cash
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 23 In CHF million, rounding consistently applied Net cash / net debt For more information on the 105.3 financial results, please see page 41 onwards. +107.7% year-on-year Operating profit 31.6 +31.7% year-
Slide 24: Company highlights 2026
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 24 Company highlights 2026 February 25 Basilea receives January 07 further USD 6 million from BARDA to Basilea and February 09 continue development Prokaryotics enter of novel antibiotic collaboration to c
Slide 25: Company highlights 2026 (continued)
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 25 May 28 Basilea receives further USD 13 million from October 28 BARDA to continue Basilea Capital Markets Day 2026 development of novel August 05 antibiotic ceftibuten- Basilea receives April 09 ledab
Slide 26: One step ahead
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 26 one step ahead Writing the next chapter of growth previous topic next topic
Slide 27: Capital Markets Day 2026
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 27 Capital Markets Day 2026 On 28 October 2026, Basilea will host its Capital Markets Day to provide investors and analysts with an update on the company’s strategic priorities, growth outlook and long-ter
Slide 28: Basilea Half-year report Letter to
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 28 previous topic next topic
Slide 29: Our portfolio
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio portfolio Financial report 29 Our portfolio Key points 30 Antifungals 32 Antibacterials 36 previous topic next topic
Slide 30: Key points
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 30 Countries with commercial partnerships in place Key points Cresemba®: USD 782 million global in-market sales (April 2025 – March 2026) 100+ Cresemba remains the leading branded antifungal for invasive
Slide 31: Basilea Half-year report Letter to
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 31 previous topic next topic
Slide 32: Antifungals: Cresemba
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 32 Antifungals Global market leader by Launched in Cresemba ® value 70+ countries (isavuconazole) Status: on the market Strong 27% Cresemba year-on-year global in-market Next milestone: continued sales gro
Slide 33: Partners deliver strong commercial performance
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 33 Our partners continue to deliver strong commercial performance, with global in-market sales reaching USD 782 million in the 12 months through to March 2026 (+27% year on year).4 This sustained momentum
Slide 34: Fosmanogepix and BAL2062
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 34 Fosmanogepix Fosmanogepix has received Qualified Infectious Disease Product (QIDP,) Orphan Drug, and Fast BAL2062 Track designations from the US Food and Drug Status: phase 3 Administration (FDA), suppo
Slide 35: Non-dilutive R&D funding for novel antifungals
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 35 Non-dilutive R&D Insights into the fosmanogepix clinical with candidemia and/or invasive candidiasis. The study enrolled its first funding for novel patient in December 2024. By 30 June development prog
Slide 36: Antibacterials: Zevtera
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 36 Antibacterials Zevtera® (ceftobiprole) First cephalosporin antibiotic Launched in 20+ Status: on the market for SAB approved in the Next milestone: establish Zevtera as a novel treatment option for Stap
Slide 37: Ceftibuten-ledaborbactam etzadroxil
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 37 Zevtera was launched in the US in July 2025 in partnership with Innoviva Specialty Thera Ceftibuten- highlighting the need for effective oral treat- ment options that could reduce or prevent peutics.
Slide 38: Basilea Half-year report Letter to
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 38 previous topic next topic
Slide 39: BAL2420 and non-dilutive R&D funding
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 39 BAL2420 Non-dilutive R&D Status: phase 1 funding for novel antibacterials Next milestone: phase 1 study completion Belonging to one of the few truly novel antibi- Basilea’s ceftobiprole phase 3 program
Slide 40: Basilea Half-year report Letter to
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 40 previous topic next topic
Slide 41: Financial report
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report Financial report 41 Financial report Key financials 42 Condensed consolidated 43 interim financial statements Notes to the condensed consolidated 47 interim financial statements previous topic
Slide 42: Key financials H1 2026
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 42 Key financials Numbers in CHF million, rounding consistently applied H1 2026 Total revenue 119.0 +14.4% year-on-year Cresemba & Zevtera related revenue of which royalty income CHF 92.3 +2.0% year-on-yea
Slide 43: Condensed consolidated balance sheets
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 43 Condensed consolidated interim financial statements Basilea Pharmaceutica Ltd, Allschwil & subsidiaries Condensed consolidated balance sheets as of June 30, 2026 (unaudited) and December 31, 2025 (audit
Slide 44: Condensed consolidated statements of operations
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 44 Basilea Pharmaceutica Ltd, Allschwil & subsidiaries Condensed consolidated statements Condensed consolidated statements of of operations comprehensive income for the six months ending June 30, 2026 and
Slide 45: Condensed consolidated statements of cash flows
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 45 Basilea Pharmaceutica Ltd, Allschwil & subsidiaries Condensed consolidated statements of cash flows for the six months ending June 30, 2026 and June 30, 2025 (unaudited) in CHF thousands Footnote 2026 2
Slide 46: Statements of changes in shareholders' equity
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 46 Basilea Pharmaceutica Ltd, Allschwil & subsidiaries Condensed consolidated statements of changes in shareholders’ equity for the six months ending June 30, 2026 and June 30, 2025 Accumulated other compr
Slide 47: Notes to the condensed consolidated interim financial statements
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 47 Basilea Pharmaceutica Ltd, Allschwil & subsidiaries Notes to the condensed consolidated interim financial statements (unaudited, all amounts in CHF unless stated otherwise) 1 Summary of significant acco
Slide 48: Notes: fair value hierarchy and foreign currency
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 48 Observable inputs reflect market data obtained from independent sources, Transactions in currencies other than the functional currency of a subsidiary while unobservable inputs reflect market assumption
Slide 49: Notes: property, plant and equipment, convertible bonds, treasury shares
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 49 Property, plant and equipment contingencies do not prevent the embedded conversion feature from being Tangible assets are recorded at cost less accumulated depreciation and considered indexed to the ent
Slide 50: Notes: leases and revenue recognition
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 50 and when lease payments increase commensurate with the standalone price — Recognition of revenue when, or as, the Company satisfies a performance for the additional right of use. When a lease modificati
Slide 51: Notes: milestone and royalty revenue recognition
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 51 and substantive development and sales milestones are recognized at a point The Company applies the general variable consideration guidance to esti- in time, or over the remaining performance period base
Slide 52: Notes: share-based compensation and taxes
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 52 Share-based compensation other comprehensive income or directly in equity. Deferred taxes represent The Company applies ASC 718 “Compensation – Stock Compensation” the estimated future tax consequences
Slide 53: Notes: pension and accounting standards
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 53 The Company further records prior service costs/credits from plan amend- In December 2023, the FASB issued ASU 2023-09, Improvements to Income ments in other comprehensive income/loss in the period of t
Slide 54: Property, plant and equipment
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 54 2 Property, plant and equipment Leasehold in CHF million Equipment improvements Total H1 2026 COST January 1, 2026 14.9 2.0 16.9 Additions 0.4 0.0 0.4 Disposals (0.2) – (0.2) June 30, 2026 15.1 2.0 17.1
Slide 55: Revenues from agreements
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 55 3 Agreements The table below summarizes revenues from all current agreements between the Company and its partners (within contract revenue: ROY = royalties, Other = milestones and upfront payments): Re
Slide 56: Notes: Pfizer and Astellas agreements
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 56 Under the terms of the Agreement, the Company was eligible for a non- For the six months ending June 30, 2026, the Company recognized CHF 0.8 refundable upfront payment of CHF 70.0 million and up to USD
Slide 57: Notes: Astellas, Asahi Kasei and Gosun agreements
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 57 For the six months ending June 30, 2026, the Company recognized royalty revenue. For the six months ending June 30, 2026, the Company recognized revenue of CHF 31.5 million (six months ending June 30, 2
Slide 58: Notes: manufacturing service and deferred revenue
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 58 The Company concluded that the commercial manufacturing service is not a In 2024, the Company received a non-refundable upfront payment of deliverable because the service is dependent on the clinical re
Slide 59: Notes: distribution agreements and BARDA OTA
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 59 Under these distribution agreements, the Company was eligible for non- For the six months ending June 30, 2026, the Company recognized CHF 0.4 refundable upfront payments of CHF 19.8 million and for sa
Slide 60: Contract with CARB-X and other receivables
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 60 Contract with CARB-X for LptA inhibitor (BAL2420) 5 Other receivables In April 2024, the Company was granted USD 0.9 million for initial preclin- ical activities on the LptA program. The funding support
Slide 61: Convertible senior unsecured bonds
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 61 to inventory produced prior to regulatory approval. The Company intends to The table below outlines the amortization and repayment related to the use such material to manufacture products for commercial
Slide 62: 2027 Bonds and share-based compensation
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 62 The 2027 Bonds are redeemable at the Company’s option since August 12, 9 Share-based compensation 2025, if the volume-weighted average price of a share on each of at least 20 out of 30 consecutive trad
Slide 63: Grant overview and treasury shares
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 63 Grant overview, key parameters for rTSR calculation and fair values: with a par value of CHF 1.00 per share) reserved for the issuance of shares under the long-term incentive plan available to directors
Slide 64: Accumulated other comprehensive income and earnings per share
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 64 Changes in accumulated other comprehensive income for the six months 11 Earnings per share ending June 30, 2026 and June 30, 2025: The weighted average number of shares outstanding and the earnings for
Slide 65: Share lending and pension plan
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 65 In 2020, the Company entered into a share lending agreement for 1,000,000 The following actuarial assumptions have been applied: registered treasury shares. These shares are deducted in the calculation
Slide 66: Leases
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 66 13 Leases The table below shows the operating lease ROU assets recorded: Operating lease contracts Buildings The Company entered into an operating lease contract for the office space in in CHF million H
Slide 67: Future lease commitments and concentration of risk
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 67 As of June 30, 2026, the future minimum commitments under ASC 842 for 15 Concentration of risk the operating lease were as follows: The Company is generally subject to credit risk related to financial i
Slide 68: Imprint
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 68 Imprint © 2026 Basilea Pharmaceutica Ltd, Allschwil Consulting, concept, design, project management, production and photography: up&up Consulting AG, Zurich Print: Kasimir Meyer AG, Wohlen Product image
Slide 69: Basilea Half-year report Letter to
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 69
Slide 70: Contact information
Basilea Half-year report Letter to 2026 shareholders Highlights Our portfolio Financial report 70 Contact information Basilea Pharmaceutica Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland Phone + 41 61 606 1111 Investor & public relations Peer Nils Schröder, Ph.D. Head of Corporate